Anormed gets FDA OK to begin Phase III trials for stem cell transplant drug

VANCOUVER (CP) - Drug developer Anormed Inc. will begin Phase III trials for its new stem cell transplant drug for cancer patients in the United States. The Vancouver company announced Thursday it had reached agreement with the U.S....More